Clinical trials: Biotherapy
Rheumatoid Arthritis
The Oxylipin Response as a New PrEdictive Biomarker of Patient Responsiveness to Biotherapy in Rheumatoid Arthritis (OPERA)
OPERA aims to better understand and predict the responsiveness of rheumatoid arthrits (RA) patients to biological disease modifying anti-rheumatic drugs (bDMARDs).
- Trial name
- OPERA (NCT05552105)
- Testing
- Blood test
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Clermont-Ferrand
Predicting Biologics Success Via VAT Assessment
Predicting Biologic Therapy Success in Ulcerative Colitis Using Intestinal Ultrasound and Fat Assessment
Our study aimed to detecting biological therapy effectiveness in UC patients using visceral fat assessment
- Trial name
- IBD/VAT (NCT07126015)
- Volunteers
- 200 people
- Sponsor
- Assiut University
Crohn Disease
Evaluation of the Efficacy and Safety of Endoscopic Dilatation and Biological Therapy in Intestinal Stenosis Due to CD
All patients with Crohn\'s disease, already undergoing biological therapy for the treatment of clinically significant intestinal stenosis and/or already undergoing endoscopic balloon dilatation during the period January 2016…
- Trial name
- NCT06603298
- Where
- Italy
- Volunteers
- 182 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rheumatoid Arthritis
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy
This two part, multi-center, open-label, single-arm study will evaluate the efficacy and safety of tocilizumab as a monotherapy or in combination with methotrexate or other conventional synthetic disease modifying antirheumatic…
- Trial name
- TOSCA (NCT02001987)
- Testing
- Tocilizumab, Methotrexate, csDMARDs
- Where
- 32 sites in France
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Biological Therapy in Treating Women With Metastatic Breast Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells.
- Trial name
- NCT00002780
- Testing
- aldesleukin, cytokine therapy, sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- St. Luke's Medical Center
Kidney Cancer
Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells.
- Trial name
- NCT00003664
- Testing
- aldesleukin, recombinant interferon alfa, fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cancer Biotherapy Research Group
Rheumatoid Arthritis
Association of Fear of Falling and Physical Activity in Rheumatoid Arthritis Comparison Before and After Biological Therapy
Primary Objective: To identify the prevalence and severity of the fear of falling in a rheumatoid population Secondary Objectives: To explore the effect the treatment with biological agents has on fear of falling and physical…
- Trial name
- NCT01071863
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Rheumatoid Arthritis
A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more participants when introduced…
- Trial name
- RADAR (NCT01162421)
- Testing
- adalimumab, Methotrexate
- Volunteers
- 77 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Melanoma (Skin)
Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining biological therapies with indomethacin and cyclophosphamide may kill more tumor cells.
- Trial name
- NCT00002535
- Testing
- aldesleukin, lymphokine-activated killer cells, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Sponsor
- St. Luke's Medical Center
Inflammatory Bowel Diseases, Crohn Disease
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease
Prospective, multicentre trial which the biologic treatment will be initiated by clinical indication. The treatment selection anti-TNFα (infliximab, adalimumab or golimumab), vedolizumab, ustekinumab and tofacitinib will be made…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- BioIBD (NCT03885713)
- Testing
- Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
- Where
- 21 sites in Spain
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Leukemia
Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells.
- Trial name
- NCT00003239
- Testing
- Recombinant Interferon Alfa, Cytarabine, Omacetaxine Mepesuccinate
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill ovarian cancer cells. Interleukin-2 combined with white blood cells that are gene-modified to recognize and kill ovarian cancer cells may be an effective…
- Trial name
- NCT00019136
- Testing
- MOv-gamma chimeric receptor gene, aldesleukin, therapeutic allogeneic lymphocytes
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Chronic Arthritis
Biomarkers in Chronic Arthritis
Use of genotyping for the optimization of treatment with biologics in chronic arthritis by looking for an association between certain alleles and response to treatment.
- Trial name
- NCT02909998
- Testing
- Blood sample
- Volunteers
- 379 people
- Sponsor
- University Hospital, Montpellier
Crohn's Disease, Ulcerative Colitis
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
Since their appearance more than a decade ago, anti-tumor necrosis factor (TNF) inhibitors have demonstrated beneficial activity in the treatment of inflammatory bowel diseases (IBD).
- Trial name
- ATAIM (NCT02508012)
- Testing
- Immuno monitoring
- Where
- France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Montpellier
Crohn's Disease
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels.
- Trial name
- U-EMPOWER (NCT06332534)
- Testing
- Upadacitinib
- Where
- 85 sites in United States, Australia and 16 more
- Volunteers
- 111 people
- Sponsor
- AbbVie
Crohn Disease
Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
With this prospective, randomized, multicentre, parallel group pragmatic non-inferiority trial, the investigators will evaluate if endoscopy-driven introduction of biological therapy is not leading to more postoperative…
- Trial name
- SOPRANO-CD (NCT05169593)
- Testing
- Biological Drug
- Where
- 28 sites in Belgium, Italy
- Volunteers
- 292 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Crohn Disease
Safety of Mesentery-embedding Surgery in Patients With Ileocolic Crohn's Disease on Biotherapy
60% of patients with Crohn's disease will undergo surgery during their lifetime and without recurrence prevention treatment, 80% of patients will have an endoscopic recurrence within 1 year of surgery.
- Trial name
- RIC-2 (NCT06856044)
- Testing
- ileocolic resection with extended mesenteric resection
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy in treating patients who have…
- Trial name
- NCT00002786
- Testing
- aldesleukin, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients
One of the main potential causes of these failures of BP therapy response is the development of Anti-drug Anti-body (ADAb) in some patients.
- Trial name
- ABI-RA (NCT02116504)
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psoriasis, Inflammation
Subclinical Impairment of Cardiovascular System in Patients With Psoriasis
A cross-sectional study will be conducted, which will include 80 young patients with psoriasis, aged 30-45 years, treated with five different types of antipsoriatic treatment, and 20 healthy patients.
- Conditions
- Psoriasis, Inflammation, Endothelial Dysfunction, Metabolic Disturbance
- Trial name
- PaS (NCT05957120)
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- University Medical Centre Ljubljana